180 related articles for article (PubMed ID: 33175321)
1. Distinctive features of pancreatic neuroendocrine neoplasms exhibiting an increment in proliferative activity during the course of the disease.
Alexandraki KI; Kaltsatou M; Kyriakopoulos G; Mavroeidi V; Kostopoulou A; Atlan K; Theocharis S; Rindi G; Grossman AB; Grozinsky-Glasberg S; Kaltsas GA
Endocrine; 2021 Apr; 72(1):279-286. PubMed ID: 33175321
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
3. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms.
Panzuto F; Cicchese N; Partelli S; Rinzivillo M; Capurso G; Merola E; Manzoni M; Pucci E; Iannicelli E; Pilozzi E; Rossi M; Doglioni C; Falconi M; Delle Fave G
PLoS One; 2017; 12(6):e0179445. PubMed ID: 28644861
[TBL] [Abstract][Full Text] [Related]
4. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
[TBL] [Abstract][Full Text] [Related]
5. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index.
Lee HE; Mounajjed T; Erickson LA; Wu TT
Endocr Pathol; 2016 Sep; 27(3):259-67. PubMed ID: 27306997
[TBL] [Abstract][Full Text] [Related]
6. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
[TBL] [Abstract][Full Text] [Related]
7. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.
Liu TC; Hamilton N; Hawkins W; Gao F; Cao D
Am J Surg Pathol; 2013 Jun; 37(6):853-9. PubMed ID: 23598967
[TBL] [Abstract][Full Text] [Related]
8. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms.
Khan MS; Luong TV; Watkins J; Toumpanakis C; Caplin ME; Meyer T
Br J Cancer; 2013 May; 108(9):1838-45. PubMed ID: 23579216
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology.
Han X; Xu X; Ma H; Ji Y; Wang D; Kuang T; Wu W; Song B; Li G; Jin G; Lou W
Endocr Connect; 2018 Feb; 7(2):355-363. PubMed ID: 29472376
[TBL] [Abstract][Full Text] [Related]
10. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
11. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
12. High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent.
Merola E; Perren A; Rinke A; Zerbi A; McNamara MG; Arsenic R; Fazio N; de Herder W; Valle JW; Gress TM; Wiedenmann B; Pascher A; Pavel ME
J Neuroendocrinol; 2022 Oct; 34(10):e13193. PubMed ID: 36306194
[TBL] [Abstract][Full Text] [Related]
13. The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasms.
Quan L; Liu Y; Cui W; Wang X; Zhang W; Wang Z; Guo C; Lu C; Hu F; Chen X
Lipids Health Dis; 2022 Jul; 21(1):58. PubMed ID: 35842659
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
15. Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.
Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
Cancer Cytopathol; 2018 Jan; 126(1):44-53. PubMed ID: 29044913
[TBL] [Abstract][Full Text] [Related]
16. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
Grillo F; Albertelli M; Annunziata F; Boschetti M; Caff A; Pigozzi S; Ferone D; Mastracci L
Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059
[TBL] [Abstract][Full Text] [Related]
17. Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.
Sigel CS; Guo H; Sigel KM; Zhang M; Rekhtman N; Lin O; Klimstra DS; Jungbluth AA; Tang LK
Cancer Cytopathol; 2017 Mar; 125(3):188-196. PubMed ID: 28094897
[TBL] [Abstract][Full Text] [Related]
18. [Accurate grading of pancreatic neuroendocrine tumors with Ki-67 index in fine-needle aspiration specimens: a comparative cytologic and histologic study].
He SR; Cui D; Gong H; Zhu YP; Chen L; Hu ST; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2017 Jun; 46(6):393-399. PubMed ID: 28591986
[No Abstract] [Full Text] [Related]
19. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
20. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
